- Home
- LPRO vs ADCT Comparison
LPRO vs ADCT Comparison
Compare LPRO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- ADCT
- Stock Information
- Founded
- LPRO 2000
- ADCT 2011
- Country
- LPRO United States
- ADCT Switzerland
- Employees
- LPRO N/A
- ADCT N/A
- Industry
- LPRO Finance: Consumer Services
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- LPRO Finance
- ADCT Health Care
- Exchange
- LPRO Nasdaq
- ADCT Nasdaq
- Market Cap
- LPRO 124.6M
- ADCT 127.9M
- IPO Year
- LPRO N/A
- ADCT 2020
- Fundamental
- Price
- LPRO $1.84
- ADCT $1.28
- Analyst Decision
- LPRO Buy
- ADCT Strong Buy
- Analyst Count
- LPRO 8
- ADCT 5
- Target Price
- LPRO $4.14
- ADCT $7.75
- AVG Volume (30 Days)
- LPRO 4.0M
- ADCT 242.8K
- Earning Date
- LPRO 05-07-2025
- ADCT 05-14-2025
- Dividend Yield
- LPRO N/A
- ADCT N/A
- EPS Growth
- LPRO N/A
- ADCT N/A
- EPS
- LPRO N/A
- ADCT N/A
- Revenue
- LPRO $17,672,000.00
- ADCT $70,837,000.00
- Revenue This Year
- LPRO $320.95
- ADCT $6.82
- Revenue Next Year
- LPRO $6.76
- ADCT $18.56
- P/E Ratio
- LPRO N/A
- ADCT N/A
- Revenue Growth
- LPRO N/A
- ADCT 1.84
- 52 Week Low
- LPRO $0.70
- ADCT $1.05
- 52 Week High
- LPRO $6.97
- ADCT $4.83
- Technical
- Relative Strength Index (RSI)
- LPRO 58.17
- ADCT 43.36
- Support Level
- LPRO $1.24
- ADCT $1.35
- Resistance Level
- LPRO $1.42
- ADCT $1.49
- Average True Range (ATR)
- LPRO 0.17
- ADCT 0.08
- MACD
- LPRO 0.18
- ADCT 0.01
- Stochastic Oscillator
- LPRO 96.26
- ADCT 26.67
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).